{"id":41197,"date":"2021-03-13T10:54:48","date_gmt":"2021-03-13T15:54:48","guid":{"rendered":"https:\/\/sciencebusiness.technewslit.com\/?p=41197"},"modified":"2021-03-13T11:12:24","modified_gmt":"2021-03-13T16:12:24","slug":"infographic-steady-growth-for-mrna-trials","status":"publish","type":"post","link":"https:\/\/technewslit.com\/sciencebusiness\/?p=41197","title":{"rendered":"Infographic – Steady Growth for mRNA Trials"},"content":{"rendered":"
\"Messenger<\/a>
Click on image for full-size view (CB Insights)<\/figcaption><\/figure>\n

13 May 2021. Thanks to the first two vaccines authorized by FDA for Covid-19, messenger RNA is now a household phrase. But to those following biotechnology, the pandemic has demonstrated mRNA’s recognized potential for vaccines and treatments that induce an immune response.<\/p>\n

Messenger RNA<\/a> is a nucleic acid based on the genetic code from DNA, and used by cells to produce amino acids in proteins for cellular functions. The technology research company CB Insights issued a report<\/a> last month on messenger RNA, including a chart showing the number of clinical trials of mRNA pharmaceuticals each year since 2005. The data, from the U.S. government’s registry at clinicaltrials.gov<\/a>, shows in 2020 and 2019, mRNA trials approached 200 each year, but since 2014 the number of trials each year already exceeded 150.<\/p>\n

The main uses for messenger RNA are vaccines and treatments for infectious diseases, as well as cancer immunotherapies. Science & Enterprise first reported on messenger RNA<\/a> in April 2012, including our first story about Moderna<\/a> in December 2012, on the company’s first venture funding round. But biotech companies are finding even more ways to use mRNA. In January we reported on Turn Biotechnologies<\/a> in Mountain View, California licensing research from Stanford University on messenger RNA to produce proteins that rejuvenate cells damaged by aging.<\/p>\n

More from Science & Enterprise:<\/p>\n